Prepare for your visit

Matthew A Nitzberg

Pulmonary Disease · Newton, MA · NPI 1053632539

One page to bring to your appointment. Every figure is as reported to CMS by drug and device makers. Payments are legal and often routine; this is context for a conversation, not a verdict.

What was reported

$323.54

in general payments reported to CMS, 2019-2025 · $87.15 in 2025

The $87.15 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).

Who reported paying

General payments only, top 5 by amount.

Astrazeneca Pharmaceuticals LP $118.13
Glaxosmithkline, LLC. $91.55
Sunovion Pharmaceuticals INC. $43.63
Inogen, INC. $36.23
Amgen INC. $34.00

Drugs and devices associated with these payments

Airsupra Inogen One G5 Oxygen Concentrator - Bluetooth Tezspire Fasenra

Association is not allocation: a product listed here means a payment was associated with it, not that money was paid to promote it. Detail covers 2023-2025.

Questions you might ask

I saw Matthew Nitzberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?
Is there a generic or alternative to this medication, and would it work as well for me?
What made you choose this particular treatment for my situation?

These are normal questions. A good clinician will welcome them.

Notes

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.

GlassScript is independent and not affiliated with CMS or any government agency. glasscript.com/doctor/905610/matthew-a-nitzberg